Assertio Therapeutics Inc (DEPO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Assertio Therapeutics Inc (DEPO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9884
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Assertio Therapeutics Inc (Assertio), formerly Depomed Inc, is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain and other diseases of the central nervous system. Its product portfolio comprises drugs for the treatment of postherpetic neuralgia caused by viral infection, herpes zoster, or nerve damage; management of mild to moderate acute pain in adults; migraine attacks in adults of 18 years of age or above; and pain in cancer patients of 18 years of age and older. The company sells its products to wholesale distributors and retail pharmacies. Assertio also licenses Acuform, its proprietary gastroretentive drug delivery technology. Assertio is headquartered in Lake Forest, Illinois, the US.

Assertio Therapeutics Inc (DEPO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Depomed Acquires Rights to Cosyntropin from Slan Medicinal 11
Depomed Acquires Rights of Cebranopadol from Grunenthal 12
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 14
Depomed Acquires US And Canadian Rights To Cambia From Nautilus Neurosciences For US$53.7 Million 16
Depomed Acquires Lazanda Nasal Spray From Archimedes Pharma 17
Depomed Acquires Zipsor From Xanodyne Pharma 18
Licensing Agreements 20
Collegium Pharma Enters into Licensing Agreement with Depomed 20
Depomed Enters Into Licensing Agreement With Janssen Pharma 21
Equity Offering 22
Depomed Plans to Raise up to USD300 Million in Public Offering of Securities 22
Depomed Files Registration Statement For Public Offering Of Securities For US$100 Million 23
Debt Offering 24
Depomed Raises USD345 million in Public Offering of 2.5% Notes Due 2021 24
Asset Transactions 26
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 26
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 27
Assertio Therapeutics Inc – Key Competitors 29
Assertio Therapeutics Inc – Key Employees 30
Assertio Therapeutics Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 08, 2018: Depomed announces second-quarter 2018 financial results 32
May 10, 2018: Depomed Announces First-Quarter 2018 Financial Results 34
Feb 27, 2018: Depomed Announces Fourth Quarter and Full Year 2017 Financial Results 35
Nov 07, 2017: Depomed Announces Third Quarter 2017 Financial Results 37
Aug 07, 2017: Depomed Announces Second Quarter 2017 Financial Results 38
May 09, 2017: Depomed Announces First Quarter 2017 Financial Results and Strategic Initiatives Aimed at Driving Sustainable Long-Term Growth and Shareholder Value 39
Feb 21, 2017: Depomed Reports Fourth Quarter and Full Year 2016 Financial Results 40
Corporate Communications 42
Oct 29, 2018: Assertio Therapeutics appoints Daniel A. Peisert as Senior Vice President and Chief Financial Officer; Current CFO Phil B. Donenberg to Retire November 30, 2018 42
Jun 05, 2018: Depomed Appoints Phillip B. Donenberg As Chief Financial Officer 43
Apr 17, 2018: Depomed Named John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications 44
Apr 17, 2018: Depomed Announces Appointment Of John B. Thomas As Senior Vice President, Investor Relations And Corporate Communications 45
Apr 02, 2018: Depomed Announces the Appointment of Stan Bukofzer as Senior Vice President and Chief Medical and Scientific Officer 46
Oct 18, 2017: Depomed Announces Appointment of Santosh J. Vetticaden, M.D., PH.D. as Senior Vice President, Chief Medical and Scientific Officer 47
Apr 25, 2017: Depomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Administration 48
Other Significant Developments 49
Aug 15, 2018: Depomed announces corporate name change to Assertio Therapeutics 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Assertio Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Depomed Acquires Rights to Cosyntropin from Slan Medicinal 11
Depomed Acquires Rights of Cebranopadol from Grunenthal 12
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 14
Depomed Acquires US And Canadian Rights To Cambia From Nautilus Neurosciences For US$53.7 Million 16
Depomed Acquires Lazanda Nasal Spray From Archimedes Pharma 17
Depomed Acquires Zipsor From Xanodyne Pharma 18
Collegium Pharma Enters into Licensing Agreement with Depomed 20
Depomed Enters Into Licensing Agreement With Janssen Pharma 21
Depomed Plans to Raise up to USD300 Million in Public Offering of Securities 22
Depomed Files Registration Statement For Public Offering Of Securities For US$100 Million 23
Depomed Raises USD345 million in Public Offering of 2.5% Notes Due 2021 24
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 26
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 27
Assertio Therapeutics Inc, Key Competitors 29
Assertio Therapeutics Inc, Key Employees 30
Assertio Therapeutics Inc, Subsidiaries 31

List of Figures
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Assertio Therapeutics Inc (DEPO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Taewoong Medical Co Ltd:企業の製品パイプライン分析2018
    Summary Taewoong Medical Co Ltd (Taewoong Medical) is a medical device company that develops and manufactures stents and other medical devices. The company offers products such as self-expandable metal stent, endoscopic RFA, endoscopic accessory, ureteral stent, airway stent, colonic stent, surgical …
  • Calamos Asset Management, Inc.:企業の戦略・SWOT・財務分析
    Calamos Asset Management, Inc. - Strategy, SWOT and Corporate Finance Report Summary Calamos Asset Management, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • UPL Ltd (UPL):企業の財務・戦略的SWOT分析
    UPL Ltd (UPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Sanmina Corp (SANM):企業の財務・戦略的SWOT分析
    Sanmina Corp (SANM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • MSM Malaysia Holdings Berhad (MSM):企業の財務・戦略的SWOT分析
    MSM Malaysia Holdings Berhad (MSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • curasan AG (CUR):医療機器:M&Aディール及び事業提携情報
    Summary curasan AG (curasan) develops, manufactures and commercializes medical devices in the field of regenerative medicine. The company offers a wide range of synthetic bone substitutes, dental and bone regeneration material products. It offers these products to orthopedic and spinal surgeons, ora …
  • Cytori Therapeutics Inc (CYTX)-医療機器分野:企業M&A・提携分析
    Summary Cytori Therapeutics Inc (Cytori) is a clinical stage regenerative medicine company. It develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) for the treatment of cardiovascular disease, orthopedic conditions and gastrointestinal disorders. The company has two …
  • Vonage Holdings Corp:企業の戦略・SWOT・財務分析
    Vonage Holdings Corp - Strategy, SWOT and Corporate Finance Report Summary Vonage Holdings Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Duke Energy Corporation (DUK)-石油・ガス分野:企業M&A・提携分析
    Summary Duke Energy Corporation (Duke Energy) is an integrated energy utility that undertakes the generation, transmission, distribution and sale of electricity; transportation and sale of natural gas; and provision of related energy services in the Southeast and Midwest regions of the US. It also p …
  • KT Corporation:企業の戦略・SWOT・財務情報
    KT Corporation - Strategy, SWOT and Corporate Finance Report Summary KT Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • American Superconductor Corp (AMSC):企業の財務・戦略的SWOT分析
    American Superconductor Corp (AMSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • bitop AG-医療機器分野:企業M&A・提携分析
    Summary Bitop AG (bitop) is a developer, manufacturer and marketer of cosmetic ingredients. The company offers extremolytes, medical devices, cosmetic ingredients and bio-stabilizer products. It offers medical devices for dermatology, allergy, cough and cold; airway diseases and dry epithelia applic …
  • Arcus SA (ARC):企業の財務・戦略的SWOT分析
    Summary Arcus SA (Arcus) is an information technology service provider that offers integrated systems for document management and mass correspondence management. Its product includes tims controlling system, which is used for telematics operation. It provides document management products such as pri …
  • Beneo GmbH:企業の戦略・SWOT・財務情報
    Beneo GmbH - Strategy, SWOT and Corporate Finance Report Summary Beneo GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • China Airlines Ltd.:企業の戦略・SWOT・財務情報
    China Airlines Ltd. - Strategy, SWOT and Corporate Finance Report Summary China Airlines Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • GeneNews Ltd (GEN):医療機器:M&Aディール及び事業提携情報
    Summary GeneNews Ltd (GeneNews) is a provider of molecular diagnostic products. The company develops and commercializes diagnostics and personalized medicine for cancer and other chronic diseases. Its Sentinel Principle is a novel approach to identifying biomarkers of body state using blood. GeneNew …
  • Deltex Medical Group Plc (DEMG):企業の財務・戦略的SWOT分析
    Summary Deltex Medical Group Plc (Deltex Medical), formerly Chalkgrove Plc, is a medical device company that develops fluid management equipment and oesophageal doppler monitoring systems. The company offers products such as cardioQ-ODM+, probes, simulator, bougies, cerebral oximetry, video laryngos …
  • X4 Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary X4 Pharmaceuticals Inc (X4 Pharma) is a clinical stage biotechnology company that develops novel therapeutics to treat cancer and rare diseases. The company’s lead drug candidate, X4P-001-LD, is in Phase 2/3 trial used for the treatment for patients with WHIM and other immunodeficiencies. It …
  • Coca-Cola Bottling Co. Consolidated (COKE):企業の財務・戦略的SWOT分析
    Coca-Cola Bottling Co. Consolidated (COKE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • G. Siempelkamp GmbH & Co KG:企業の戦略的SWOT分析
    G. Siempelkamp GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆